Shield Bio

At Shield, we’re ensuring that antibiotic resistance doesn’t become more deadly than cancer.

In 2050 more people will be dying of antibiotic resistant pathogens than cancer. Infections that were once treatable with a simple oral antibiotics are now requiring complex, painful treatments and resulting in serious health complications for patients.

Gonorrhea is one such infection, having become resistant to over 10 different antibiotics, they have only one treatment that is still effective and resistance to this has already begun to emerge. With 820,000 new infections every year in the US, antibiotic resistance will spread quickly, which is why the CDC has resistant gonorrhea at an urgent threat level, the highest level available.

Shield's novel genomic testing platform enables STI clinics to identify the antibiotic resistant strains of gonorrhea and other pathogens that their patients have, so they can select the correct antibiotics and halt the spread of antibiotic resistance.

Shield Bio headquartered in United States, North America, operates in the Biotechnology, Health Care, Genetics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $580.8M in funding across 48 round(s). With a team of 11-50 employees, Shield Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Shield Bio, raised $8.0M. Discover more about their projects, partnerships, and impact on our platform.